COMPARE · Reviewed July 29, 2026

CL vs MO

Verdict: Side-by-side breakdown using the Bull Rankings model. CL scored 40.2, MO scored 42.9 — MO leads.
Compare another set
CL
Colgate-Palmolive Co
Consumer products · Quality-Growth
40.2
$91.20 · $73.6B
Score gap
2.7
MO leads
MO
Altria Group Inc
Tobacco · Quality-Growth
42.9
$68.09 · $115.3B
THE BULL RANKINGS SCORECARD40/ 100 · BULL SCOREPEER MEDIANQUALITY90GROWTH46VALUE15
THE BULL RANKINGS SCORECARD43/ 100 · BULL SCOREPEER MEDIANQUALITY97GROWTH14VALUE60
CL
stronger →← stronger
MO
90
Qualityreturns · margins · balance sheet
97
46
Growthrevenue & earnings expansion
14
15
Valuevaluation vs sector peers
60
MO is stronger on 2 of 3 pillars.
CL
MO
$3.8bB
FCF
$8.6bB+
+4.3%C+
Rev
-1.1%D+
35.6xC
P/E
15.6xB+
8.38D
PEG
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
CL
MO
29% above
Price vs fair valuelower is cheaper
0% below
~10%/yr
Growth the price implies10-yr FCF · lower = less priced in
~1%/yr
-24%
1-yr DCF upside
+6%
-22%
5-yr DCF upside
+0%
-21%
10-yr DCF upside
-7%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
CL
Why this score
  • Durable high returns
MO
Why this score
  • Short track record
CLColgate-Palmolive Co
Consumer products · $91.20 · beta 0.33
Why now
Consumer products · market cap $73.6b. 8% off the 52-week high of $99.33.
Moat
ROE 475% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $73.6b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trailing P/E 36x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
MOAltria Group Inc
Tobacco · $68.09 · beta 0.50
Why now
Tobacco · market cap $115.3b. 12% off the 52-week high of $77.06.
Moat
Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 150% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $115.3b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Dividend payout 87% of earnings on a 5.6% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.